Digital breast tomosynthesis (DBT), commonly known as 3D mammography, is an advanced breast imaging technology that captures multiple low-dose X-ray images from different angles to create detailed, layered views of breast tissue. Unlike conventional 2D mammography, DBT provides enhanced visualization of breast structures, helping radiologists detect abnormalities that may otherwise be hidden by overlapping tissue.
As breast cancer remains one of the most commonly diagnosed cancers worldwide, healthcare providers are increasingly adopting DBT to improve early detection rates and diagnostic confidence. The technology is particularly valuable for women with dense breast tissue, where traditional mammography may have limitations. Additionally, advancements such as synthesized 2D imaging, AI-assisted image analysis, optimized radiation dose, and integrated biopsy guidance are further strengthening DBT’s role in modern breast imaging.
According to BIS Research, the global digital breast tomosynthesis market was valued at $925.7 million in 2025 and is projected to reach $2,894.6 million by 2036, growing at a CAGR of 10.99% during the forecast period 2026-2036.
Download the complete TOC and Request Sample Report
• Growing demand for early breast cancer detection and advanced screening solutions
• Superior cancer detection rates and reduced recall rates compared to conventional mammography
• Rising adoption of DBT for women with dense breast tissue
• Integration of AI-assisted image interpretation and workflow automation tools
• Expansion of breast cancer screening programs across developed healthcare markets
• Technological advancements including synthesized 2D imaging, dose optimization, and faster acquisition times
According to Principal Consultant at BIS Research:
"The digital breast tomosynthesis market is evolving from an advanced imaging upgrade to an essential component of modern breast care. Its proven ability to improve cancer detection while reducing unnecessary recalls is driving adoption across screening and diagnostic pathways. Developed markets continue to lead implementation due to strong reimbursement support and established screening infrastructure, while emerging regions are gradually increasing adoption through investments in advanced diagnostic capabilities. As personalized screening models gain momentum and AI-powered imaging solutions become more prevalent, DBT is expected to play an increasingly important role in precision breast imaging and early cancer detection."
The digital breast tomosynthesis market is projected to grow from $925.7 million in 2025 to $2,894.6 million by 2036, registering a CAGR of 10.99% during the forecast period.
Key market participants include Allengers, DMS Group, FUJIFILM Corporation, GE Healthcare, Genoray Co., Ltd., Hologic, Inc., IMS Giotto S.p.A., Metaltronica S.p.A., Planmed Oy, Siemens Healthineers, and Shanghai United Imaging Healthcare Co., Ltd.
Hospitals and ambulatory surgical centers account for the largest market share due to their integrated screening, diagnostic, biopsy, and treatment capabilities, along with stronger infrastructure and higher patient volumes.
North America dominates the digital breast tomosynthesis market, supported by established breast cancer screening programs, favorable reimbursement policies, widespread DBT adoption, and advanced healthcare infrastructure.
Want to Make Data-Backed Moves in the Breast Imaging Market?
BIS Research provides expert-driven market intelligence, competitive benchmarking, technology assessment, and strategic advisory services across medical devices, diagnostics, healthcare technologies, and life sciences markets.
